Abatacept
"Abatacept" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS.
Descriptor ID |
D000069594
|
MeSH Number(s) |
D12.776.124.790.651.114.580.225 D12.776.377.715.548.114.580.225
|
Concept/Terms |
CTLA-4-Ig- CTLA-4-Ig
- Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin
- Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin
- CTLA4-Ig
- CTLA4-Ig Immunoconjugate
- CTLA4 Ig Immunoconjugate
- Immunoconjugate, CTLA4-Ig
- CTLA4-Fc
|
Below are MeSH descriptors whose meaning is more general than "Abatacept".
Below are MeSH descriptors whose meaning is more specific than "Abatacept".
This graph shows the total number of publications written about "Abatacept" by people in this website by year, and whether "Abatacept" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 1 | 1 | 1998 | 0 | 1 | 1 | 1999 | 0 | 1 | 1 | 2000 | 0 | 1 | 1 | 2001 | 0 | 2 | 2 | 2002 | 0 | 2 | 2 | 2003 | 0 | 2 | 2 | 2004 | 0 | 1 | 1 | 2005 | 0 | 2 | 2 | 2006 | 0 | 3 | 3 | 2007 | 0 | 1 | 1 | 2008 | 0 | 1 | 1 | 2009 | 0 | 2 | 2 | 2010 | 0 | 2 | 2 | 2011 | 0 | 1 | 1 | 2012 | 0 | 1 | 1 | 2013 | 0 | 3 | 3 | 2014 | 0 | 3 | 3 | 2017 | 2 | 0 | 2 | 2018 | 0 | 1 | 1 | 2021 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Abatacept" by people in Profiles.
-
Qayed M, Watkins B, Gillespie S, Bratrude B, Betz K, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Langston A, Kean LS, Horan JT. Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. Blood Adv. 2022 02 08; 6(3):746-749.
-
Inamo J, Kaneko Y, Kikuchi J, Takeuchi T. High serum IgA and activated Th17 and Treg predict the efficacy of abatacept in patients with early, seropositive rheumatoid arthritis. Clin Rheumatol. 2021 Sep; 40(9):3615-3626.
-
Sobolewska B, Baglivo E, Edwards AO, Kramer M, Miserocchi E, Palestine AG, Schwab IR, Zamir E, Doycheva D, Zierhut M. Drug-induced Sarcoid Uveitis with Biologics. Ocul Immunol Inflamm. 2022 May 19; 30(4):907-914.
-
Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021 06 10; 39(17):1865-1877.
-
Ptacek J, Hawtin RE, Sun D, Louie B, Evensen E, Mittleman BB, Cesano A, Cavet G, Bingham CO, Cofield SS, Curtis JR, Danila MI, Raman C, Furie RA, Genovese MC, Robinson WH, Levesque MC, Moreland LW, Nigrovic PA, Shadick NA, O'Dell JR, Thiele GM, Clair EWS, Striebich CC, Hale MB, Khalili H, Batliwalla F, Aranow C, Mackay M, Diamond B, Nolan GP, Gregersen PK, Bridges SL. Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. PLoS One. 2021; 16(1):e0244187.
-
Woodle ES, Kaufman DB, Shields AR, Leone J, Matas A, Wiseman A, West-Thielke P, Sa T, King EC, Alloway RR. Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial. Am J Transplant. 2020 04; 20(4):1039-1055.
-
Plenter RJ, Coulombe MG, Roybal HM, Lin CM, Gill RG, Zamora MR, Grazia TJ. C-kit-derived CD11b+ cells are critical for cardiac allograft prolongation by autologous C-kit+ progenitor cells. Cell Immunol. 2020 01; 347:104023.
-
Rivard CJ, Tanabe T, Lanaspa MA, Watanabe H, Nomura S, Andres-Hernando A, Garth K, Sekijima M, Ishimoto T, Ariyoshi Y, Garcia GE, Shah J, Lennan B, Tasaki M, Pomposelli T, Shimizu A, Sachs DH, Johnson RJ, Yamada K. Upregulation of CD80 on glomerular podocytes plays an important role in development of proteinuria following pig-to-baboon xeno-renal transplantation - an experimental study. Transpl Int. 2018 10; 31(10):1164-1177.
-
Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. J Rheumatol. 2018 08; 45(8):1085-1092.
-
Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol. 2017 04; 69(4):846-853.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|